Tested & Approved RAC-US Study Materials Download Free Updated 100 Questions
Regular Free Updates RAC-US Dumps Real Exam Questions Test Engine
The Regulatory Affairs Certification (RAC) US exam is a certification program designed to test the regulatory knowledge of individuals working in the pharmaceutical and medical device industry. The RAC-US exam is administered by the Regulatory Affairs Professionals Society (RAPS), a professional organization dedicated to promoting regulatory excellence in the healthcare industry. RAC-US exam is designed to help regulatory professionals demonstrate their expertise in regulatory affairs and enhance their professional credentials.
The RAC-US certification is recognized as a mark of excellence in regulatory affairs. Regulatory Affairs Certification (RAC) US certification demonstrates that a regulatory professional has the knowledge and skills required to navigate the complex regulatory environment in the US. The RAC-US certification is also a valuable asset for professionals who are seeking career advancement in the pharmaceutical, medical device, and biotech industries. Employers recognize the value of the RAC-US certification and often seek out certified professionals when hiring for regulatory affairs positions.
NEW QUESTION # 12
Which of the following is the MOST desirable timing and approach for a regulatory affairs professional who wants to provide feedback on proposed new regulations?
- A. After the enactment of the regulation, through a product-specific meeting
- B. Before the enactment of the regulation, through formal comments gathering process
- C. After the enactment of the regulation, through the industry representative
- D. Before the enactment of the regulation, through the industry representative
Answer: B
NEW QUESTION # 13
According to ISO 14971, what is the FIRST step when developing a risk management plan for a medical device?
- A. Risk estimation
- B. Risk control
- C. Risk analysis
- D. Risk management
Answer: C
NEW QUESTION # 14
Which of the following is NOT required to be included in a marketing application?
- A. Administrative forms
- B. Evidence of fee payment
- C. Final printed label
- D. Quality, safety, and efficacy Information
Answer: B
NEW QUESTION # 15
A company is developing a device-drug combination product. Which of the following should be evaluated FIRST in order to determine the applicable guidance documents?
- A. Determination of primary mode of action
- B. Guidance documents for the device
- C. Approved indications of the drug
- D. Determination of product design deliverables
Answer: D
NEW QUESTION # 16
During routine surveillance, a regulatory authority sent a company the following communication: "Hepatotoxicity and suicidal behavior were identified as potential safety issues for the company's product. The regulatory authority is evaluating these issues to determine the need for any regulatory action." Which action would be the most appropriate
FIRST step for the company to take?
- A. Repeat the Hepatotoxicity tests and send the results to the regulatory authority.
- B. Contact the regulatory authority to discuss its findings.
- C. Wait for the regulatory authority's final publication on its findings.
- D. Contact the regulatory authority to argue that its conclusions are wrong.
Answer: B
NEW QUESTION # 17
According to ICH, how many stability time points are normally required to establish a two- year shelf life for a product?
- A. 0
- B. 1
- C. 2
- D. 3
Answer: D
NEW QUESTION # 18
The regulatory authority contacts the regulatory affairs professional regarding a complaint about a drug produced by the company. A consumer reported to the regulatory authority that the tablets have a slightly different color and break easily.
Which of the following actions should the regulatory affairs professional take?
- A. Respond to the regulatory authority that the product subject to the complaint is most likely a counterfeit product.
- B. Ask that the regulatory authority provide the actual product subject to the complaint.
- C. Respond to the regulatory authority that the company will provide copies of the relevant
QC records for batch release. - D. Ask that the regulatory authority provide the batch number printed on the packaging of the affected product.
Answer: D
NEW QUESTION # 19
In preparation for the development of a new line of products, a regulatory affairs professional is asked to prepare a short presentation for senior management. Which of the following topics is MOST important to cover?
- A. Previous actions taken by regulatory authorities on similar products
- B. Regulatory requirements for labeling and packaging
- C. Potential clinical sites for the Phase III clinical trial
- D. Capacity of the manufacturing facilities to fully produce the new product
Answer: A
NEW QUESTION # 20
The regulatory authority in Country X issued a request for a mandatory product recall in
Country X due to serious injuries to patients. This product also is distributed in Country Y.
What should the regulatory affairs professional of the product's manufacturer FIRST do in
Country Y?
- A. Draft a formal letter to customers in Country Y about this recall.
- B. Initiate a mandatory recall of the product in Country Y.
- C. Prepare the legal team in Country Y for possible litigations.
- D. Review alt distribution records and complaints reported in Country Y.
Answer: D
NEW QUESTION # 21
Which question is pertinent to demonstrate a new pharmaceutical's effectiveness during evaluation by a reimbursement agency?
- A. "Has the product been approved for mor&4nan 10 years?"
- B. "Is the product an established gold standard?"
- C. "Is the product better than currently available alternatives?"
- D. "Is the product profitable for the manufacturer?"
Answer: C
NEW QUESTION # 22
A company is developing a new medical device.
During which initial stage is it MOST appropriate (or a regulatory affairs professional to become involved?
- A. Concept development and validation
- B. Early technical design and product release
- C. Concept development and early technical design
- D. Product release and validation
Answer: C
NEW QUESTION # 23
Which of the following double-blind clinical trial designs would be MOST appropriate for a
Phase III study with a new product intended to treat an acute life-threatening disease with less than optimal available therapy?
- A. Placebo-controlled
- B. Cross-over
- C. Dose-ranging
- D. Active-controlled
Answer: B
NEW QUESTION # 24
During the review of a design dossier, the reviewer asks why the company has only carried out a top-down risk approach. The reviewer is referring to which of the following?
- A. Fault tree analysis
- B. ISO 14971 risk analysis
- C. Hazard and operability study
- D. Failure mode and effect analysis
Answer: B
NEW QUESTION # 25
Which of the following is NOT considered a serious adverse event in a cardiovascular clinical trial?
- A. Subject's hospitalization is prolonged during the clinical trial.
- B. Subject's hospitalization is due to an unscheduled hip operation.
- C. Subject is hospitalized for the purpose of product administration.
- D. Subject is hospitalized due to complications of the product administration.
Answer: C
NEW QUESTION # 26
A company receives multiple complaints regarding the text included on a recently launched product's label. What action should the regulatory affairs professional take FIRST?
- A. Compare the approved text with the product label
- B. Recommend an immediate product recall.
- C. Inform the production team.
- D. Notify the regulatory authority.
Answer: A
NEW QUESTION # 27
Company X has a patent for an anti-inflammatory drug that will expire in one year. In order to minimize the effect of the patent expiration, which is the BEST action for the company to take?
- A. Explore litigation strategy for patent infringements on the drug.
- B. Develop a generic version of the drug.
- C. Develop a better brand-name drug in the same class.
- D. Conduct a Phase III study for a new unrelated indication of the drug.
Answer: B
NEW QUESTION # 28
Which of the following statements regarding export regulations for an approved product is CORRECT?
- A. The product must not be in conflict with the laws of the country to which it is intended for export.
- B. The product must not be labeled on the outside of the shipping package that it is intended for export.
- C. The product must not be sold or offered for sale in domestic commerce.
- D. The product must not be in accord with the specifications of the foreign purchaser.
Answer: A
NEW QUESTION # 29
Company X and Company Y both have products for the treatment of rare genetic diseases.
Company X would like to acquire Company Y but does not know enough about Company Y to make an offer.
What is the MOST appropriate approach that Company X should take to acquire more information about Company Y?
- A. Perform a thorough library search to gather detailed information on Company Y.
- B. Request the needed information from the Board of Directors of Company Y.
- C. Recruit a professional to gather confidential intelligence on Company Y.
- D. Enter into an agreement with Company Y to perform due diligence.
Answer: D
NEW QUESTION # 30
A company's product was approved by a regulatory authority with the condition that further studies must be completed prior to full approval of the product.
To minimize product-associated risk to patients during the period of conditional approval, what is the LEAST effective way to achieve this goal?
- A. Label the product for use in appropriate populations.
- B. Educate patients and healthcare providers on how to use the product
- C. Delay product launch until required studies are completed.
- D. Promote off-label use to a carefully selected patient population.
Answer: D
NEW QUESTION # 31
......
The Regulatory Affairs Certification (RAC) US exam is a professional certification program offered by the Regulatory Affairs Professionals Society (RAPS). The RAC-US certification program is designed to validate the knowledge and expertise of regulatory affairs professionals in the United States. RAC-US exam covers a wide range of topics related to regulatory affairs, including FDA regulations, drug development, clinical trials, medical devices, biologics, and healthcare compliance.
Pass RAPS RAC-US Exam in First Attempt Easily: https://www.actual4cert.com/RAC-US-real-questions.html
Practice Test Questions Verified Answers As Experienced in the Actual Test!: https://drive.google.com/open?id=1P84rsxywG8KhU4EVVN-thQl_ejmFZPcD